Genomic landscape and immune phenotype of malignant pleural mesothelioma.
Meera Patel(Wayne State University), Hirva Mamdani(Wayne State University), Rebecca Feldman(Caris Life Sciences (United States)), W. Michael Korn(Itasca Community College), Stephen V. Liu(Georgetown University), Alexander I. Spira(Virginia Cancer Specialists), Sachin Gopalkrishna Pai(USA Mitchell Cancer Institute), Misako Nagasaka(University of California, Irvine), Edward S. Kim(The University of Texas MD Anderson Cancer Center), Chul Kim(Georgetown University), Antoinette J. Wozniak(Wayne State University), Luis E. Raez(Florida International University), Gilberto Lopes(University of Miami), Andrew Elliott(Caris Life Sciences (United States))
Cited by 6
Related Papers
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k